Yiwen Zhu, Katherine H Shutta, Tianyi Huang, Raji Balasubramanian, Oana A Zeleznik, Clary B Clish, Julián Ávila-Pacheco, Susan E Hankinson, Laura D Kubzansky
{"title":"持续的创伤后应激障碍症状与与长期健康相关的血浆代谢改变有关:一项针对女性的全代谢组调查","authors":"Yiwen Zhu, Katherine H Shutta, Tianyi Huang, Raji Balasubramanian, Oana A Zeleznik, Clary B Clish, Julián Ávila-Pacheco, Susan E Hankinson, Laura D Kubzansky","doi":"10.1101/2024.08.07.24311628","DOIUrl":null,"url":null,"abstract":"Background: Posttraumatic stress disorder (PTSD) is characterized by severe distress and associated with cardiometabolic diseases. Studies in military and clinical populations suggest dysregulated metabolomic processes may be a key mechanism. Prior work identified and validated a metabolite-based distress score (MDS) linked with depression and anxiety and subsequent cardiometabolic diseases. Here, we assessed whether PTSD shares metabolic alterations with depression and anxiety and also if additional metabolites are related to PTSD. Methods: We leveraged plasma metabolomics data from three subsamples nested within the Nurses' Health Study II, including 2835 women with 2950 blood samples collected across three timepoints (1996-2014) and 339 known metabolites consistently assayed by mass spectrometry-based techniques. Trauma and PTSD exposures were assessed in 2008 and characterized as follows: lifetime trauma without PTSD, lifetime PTSD in remission, and persistent PTSD symptoms. Associations between the exposures and the MDS or individual metabolites were estimated within each subsample adjusting for potential confounders and combined in random-effects meta-analyses. Results: Persistent PTSD symptoms were associated with higher levels of the previously developed MDS for depression and anxiety. Out of 339 metabolites, we identified nine metabolites (primarily elevated glycerophospholipids) associated with persistent symptoms (false discovery rate<0.05). No metabolite associations were found with the other PTSD-related exposures. Conclusions: As the first large-scale, population-based metabolomics analysis of PTSD, our study highlighted shared and distinct metabolic differences linked to PTSD versus depression or anxiety. We identified novel metabolite markers associated with PTSD symptom persistence, suggesting further connections with metabolic dysregulation that may have downstream consequences for health.","PeriodicalId":501071,"journal":{"name":"medRxiv - Epidemiology","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Persistent PTSD symptoms are associated with plasma metabolic alterations relevant to long-term health: A metabolome-wide investigation in women\",\"authors\":\"Yiwen Zhu, Katherine H Shutta, Tianyi Huang, Raji Balasubramanian, Oana A Zeleznik, Clary B Clish, Julián Ávila-Pacheco, Susan E Hankinson, Laura D Kubzansky\",\"doi\":\"10.1101/2024.08.07.24311628\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Posttraumatic stress disorder (PTSD) is characterized by severe distress and associated with cardiometabolic diseases. Studies in military and clinical populations suggest dysregulated metabolomic processes may be a key mechanism. Prior work identified and validated a metabolite-based distress score (MDS) linked with depression and anxiety and subsequent cardiometabolic diseases. Here, we assessed whether PTSD shares metabolic alterations with depression and anxiety and also if additional metabolites are related to PTSD. Methods: We leveraged plasma metabolomics data from three subsamples nested within the Nurses' Health Study II, including 2835 women with 2950 blood samples collected across three timepoints (1996-2014) and 339 known metabolites consistently assayed by mass spectrometry-based techniques. Trauma and PTSD exposures were assessed in 2008 and characterized as follows: lifetime trauma without PTSD, lifetime PTSD in remission, and persistent PTSD symptoms. Associations between the exposures and the MDS or individual metabolites were estimated within each subsample adjusting for potential confounders and combined in random-effects meta-analyses. Results: Persistent PTSD symptoms were associated with higher levels of the previously developed MDS for depression and anxiety. Out of 339 metabolites, we identified nine metabolites (primarily elevated glycerophospholipids) associated with persistent symptoms (false discovery rate<0.05). No metabolite associations were found with the other PTSD-related exposures. Conclusions: As the first large-scale, population-based metabolomics analysis of PTSD, our study highlighted shared and distinct metabolic differences linked to PTSD versus depression or anxiety. We identified novel metabolite markers associated with PTSD symptom persistence, suggesting further connections with metabolic dysregulation that may have downstream consequences for health.\",\"PeriodicalId\":501071,\"journal\":{\"name\":\"medRxiv - Epidemiology\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Epidemiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.08.07.24311628\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.07.24311628","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:创伤后应激障碍(PTSD创伤后应激障碍(PTSD)的特征是严重的痛苦,并与心脏代谢疾病相关。对军队和临床人群的研究表明,代谢组过程失调可能是一个关键机制。之前的研究发现并验证了基于代谢组的痛苦评分(MDS)与抑郁和焦虑以及随后的心脏代谢疾病有关。在此,我们评估了创伤后应激障碍是否与抑郁和焦虑有共同的代谢改变,以及是否有其他代谢物与创伤后应激障碍有关。研究方法我们利用了嵌套在 "护士健康研究 II"(Nurses' Health Study II)中的三个子样本的血浆代谢组学数据,其中包括 2835 名女性在三个时间点(1996-2014 年)采集的 2950 份血液样本,以及通过质谱技术持续测定的 339 种已知代谢物。2008年对创伤和创伤后应激障碍暴露进行了评估,其特征如下:终生遭受创伤但未患创伤后应激障碍、终生创伤后应激障碍缓解以及创伤后应激障碍症状持续存在。在对潜在混杂因素进行调整后,在每个子样本中估算了暴露与 MDS 或单个代谢物之间的关联,并在随机效应元分析中进行了合并。结果持续的创伤后应激障碍症状与之前开发的抑郁和焦虑MDS水平较高有关。在 339 种代谢物中,我们发现有 9 种代谢物(主要是甘油磷脂的升高)与持续性症状有关(假发现率为 0.05)。没有发现代谢物与其他创伤后应激障碍相关暴露有关。结论作为首个大规模、基于人群的创伤后应激障碍代谢组学分析,我们的研究强调了创伤后应激障碍与抑郁或焦虑相关的共同和独特的代谢差异。我们发现了与创伤后应激障碍症状持续相关的新型代谢物标记物,这表明代谢失调与创伤后应激障碍有进一步的联系,可能会对健康产生下游影响。
Persistent PTSD symptoms are associated with plasma metabolic alterations relevant to long-term health: A metabolome-wide investigation in women
Background: Posttraumatic stress disorder (PTSD) is characterized by severe distress and associated with cardiometabolic diseases. Studies in military and clinical populations suggest dysregulated metabolomic processes may be a key mechanism. Prior work identified and validated a metabolite-based distress score (MDS) linked with depression and anxiety and subsequent cardiometabolic diseases. Here, we assessed whether PTSD shares metabolic alterations with depression and anxiety and also if additional metabolites are related to PTSD. Methods: We leveraged plasma metabolomics data from three subsamples nested within the Nurses' Health Study II, including 2835 women with 2950 blood samples collected across three timepoints (1996-2014) and 339 known metabolites consistently assayed by mass spectrometry-based techniques. Trauma and PTSD exposures were assessed in 2008 and characterized as follows: lifetime trauma without PTSD, lifetime PTSD in remission, and persistent PTSD symptoms. Associations between the exposures and the MDS or individual metabolites were estimated within each subsample adjusting for potential confounders and combined in random-effects meta-analyses. Results: Persistent PTSD symptoms were associated with higher levels of the previously developed MDS for depression and anxiety. Out of 339 metabolites, we identified nine metabolites (primarily elevated glycerophospholipids) associated with persistent symptoms (false discovery rate<0.05). No metabolite associations were found with the other PTSD-related exposures. Conclusions: As the first large-scale, population-based metabolomics analysis of PTSD, our study highlighted shared and distinct metabolic differences linked to PTSD versus depression or anxiety. We identified novel metabolite markers associated with PTSD symptom persistence, suggesting further connections with metabolic dysregulation that may have downstream consequences for health.